• June 3-6, 2024
  • San Diego Convention Center, California


Charles Kim

Charles Kim, JD

Co-Chair - Global Capital Markets Practice Group
Cooley LLP
Charlie Kim is Co-Chair of Cooley's Global Capital Markets Practice Group. He's also Co-Chair of its API Affinity Group and a member of its DEI Advisory Council. He is a nationwide leader in capital markets transactions and has worked on 200+ successfully completed public company securities offerings since 2019 (including Uber's $8.1 billion IPO and 3 of the 5 biggest biotechnology IPOs to date). Charlie focuses on representing US and non-US issuers, investment banking firms and venture capital firms in public offerings and private placements of equity and debt securities. Charlie has worked on securities offerings by leading healthcare companies such as: AbCellera, Accelerate, ACELYRIN, Acutus, Advaxis, Agenus, Akari, Akcea, Akero, Allogene, Ambrx, Amylin, Anadys, AnaptysBio, Angion, Annexon, Anthera, Apogee, Applied Molecular Transport, Arcadia, Arcus, Arcutis, Ardea, Arena, Aridis, Ascendis, ASLAN, Athira, Audentes, Avidity, Biomea, Cadence, Castlight, Cerus, CG Oncology, Cidara, Corcept, Crinetics, Cue, Cyan, Cytori, Day One, Dermira, Design, DICE, Doximity, Dynavax, Eidos, Elevation, Erasca, Exagen, Evofem, Five Prime, Gemphire, Global Blood, Gossamer, Gracell, Graphite Bio, Gritstone, Guardant Health, Halozyme, Health Catalyst, Healthcare Royalty, HealthEquity, Horizon, IGM, Ignyta, Immune Design, IMV, Inhibrx, Inovio, Invitae, Ionis, Janux, Jazz Pharmaceuticals, Kamada, Kinnate, Kite, Kronos, Livongo, Longboard, Lyell, MannKind, MethylGene, Minerva, Mirati, NantHealth, NantKwest, Nektar, Neon, Neumora, Neurocrine, ObsEva, Olink, Ooma, Optimer, ORIC, Otonomy, Pernix, Phathom, Poseida, PRA Holdings, PROCEPT, ProNAi, ProQR, Quidel, Radiant, Rani, Raptor, RayzeBio, Reata, Receptos, Regulus, ReSearch Pharmaceutical Services, Sana, Sangamo, Santarus, Savara, Seattle Genetics, Senomyx, Sequenom, ShockWave, Sierra, Silverback, Singular Genomics, Somaxon, Strongbridge, Structure, Surface Oncology, Sutro, Syndax, Taiwan Liposome Company, Tangoe, Tarsus, Third Harmonic, TRACON, Treace, Tricida, Trius, TriVascular, Vaxcyte, Ventyx Biosciences, Verona, Vical, Vir, Vital Therapies, Vor, Xencor, Xenon, XenoPort, Zealand Pharma, Zentalis, Zogenix, Zymeworks, 4D Molecular Therapeutics,10x Genomics and 89bio.
Speaking In


Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.